Allergy Therapeutics plc provided revenue guidance for the six months ended December 31, 2021. For the six months, the company expects revenues to be £48.7 million (2020: £54.0 million), representing a 10% reduction on a reported basis (down 5% on constant currency basis). This is primarily due to the previously disclosed strategic streamlining of non-differentiated older products to maintain focus on short course subcutaneous immunotherapy (SCIT) and innovative allergy treatments.

On this revised basis revenues have increased 3% on a like for like product and phasing basis (on constant currency basis).